



**UROLIFT<sup>®</sup>**

**BPH Relief. In Sight.<sup>™</sup>**

**OPEN UP TO A WHOLE NEW  
APPROACH TO BPH**

# UROLIFT®

## First Line Treatment

### The UroLift® System Treatment

A minimally invasive approach to treating BPH that lifts or holds the enlarged prostate tissue out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.

- **Immediate, visible result**
- **Rapid symptom relief**
- **No tissue removal or ablation**
- **Minimal downtime**
- **Preservation of sexual function**



*Pre-Treatment*



*Post-Treatment*

# UROLIFT®

## Redefining BPH Treatment

**11.9 Million Men** in the U.S. are Treated for BPH/LUTS



Watchful Waiting

**48%**

5.7 Million Patients



Drugs

**51%**

6.1 Million Patients

**UROLIFT®**

is a new option for patients looking for an alternative to drugs or major surgery

Surgery/Procedure

Yet Only **1%** Elect Surgery

142,000 Patients



Each Year, **~20% or 1.2 Million** discontinue drugs (inadequate relief, side effects, etc.)

NeoTract US Market Model estimates for 2013 based on IMS Health Drug and Procedure data



# UROLIFT®

## Straightforward Approach

The UroLift® Delivery Device is inserted transurethraly through a rigid sheath under cystoscopic visualization in order to reach the targeted area of obstruction.

The obstructing prostatic lobes are retracted by small permanent UroLift Implants which are deployed via a needle that comes out of the delivery device.

Each UroLift Delivery Device contains one UroLift Implant. Typically, 4-5 UroLift Implants are placed into the prostate.




UroLift®  
Permanent Implant



UroLift®  
Delivery Device

# UROLIFT®

## Significant Improvement Without Significant Downsides



\*ED – Erectile Dysfunction \*\*EjD – Ejaculatory Dysfunction

Roehrborn, J Urology 2013; McNicholas, Eur Urology 2013; Chin, Urology 2012; EAU Guidelines 2011; AUA Guidelines 2010 and 2003

1. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.

# 0% Ejaculatory Dysfunction

# 0% Erectile Dysfunction

No instances of de novo, sustained erectile or ejaculatory dysfunction.

# UROLIFT®

## Strong Clinical Results

- Endoscopic results can be immediately confirmed post-procedure.
- Patients may experience symptom relief as early as 2 weeks post-procedure.
- UroLift® System treatment does not preclude future UroLift, TURP or laser procedures.




Canadian J. of Urology, Multi-Center Study (n=51) 2014  
British J. Urology, Crossover Study (n=53) 2013  
J. of Urology, L.I.F.T. Study (n=206, 1 yr) 2013  
J. of Sexual Medicine, USA Sexual Function (n=140, 1 yr) 2013  
EU J. of Urology, EU Registration (n=102, 1 yr) 2013  
Archivos Españoles Urología, Spanish Study (n=20) 2013  
Urology, 2 Year Multi-Center Study (n=64, 2 yr) 2012  
J. Sexual Medicine, Preserves Sexual Function (n=64, 1 yr) 2012  
Progrès en Urologie, Single Center French Study (n=4) 2012  
Canadian J. of Urology, Technique (n=50) 2012  
British J. Urology, First in Man (n=19, 1 yr) 2011

# UROLIFT®

## L.I.F.T. Study Results Corroborate Prior Studies

**206-patient** L.I.F.T. IDE Study, a multi-center, randomized, blinded study. All primary and secondary endpoints were met. Patients experienced rapid symptomatic improvement, increased urinary flow rates, preserved sexual function and a significant improvement in Quality of Life.



*Chin et al.: Urology 2012; McNicholas et al.: European Urology 2013; Roehrborn et al.: Journal of Urology 2013*

	3 Month Change from Baseline			12 Month
	UroLift	Control	Difference	UroLift
AUASI	11.1	5.9	0.003	10.8
Qmax (ml/s)	4.28	1.98	p =0.005	4.02
QOL	2.2	1.0	p <0.001	2.4
BPHII	3.9	2.1	p <0.001	4.0

*No instances of de novo, sustained erectile or ejaculatory dysfunction*

The logo for UroLift, featuring the word "URO" in a standard sans-serif font, followed by a stylized yellow and orange circular graphic, and then "LIFT" in a standard sans-serif font with a registered trademark symbol.

**For additional information and surgical videos  
visit [UroLift.com](http://UroLift.com)**

**Customer Service • 877.408.9628  
Reimbursement Resource Center • 800.651.8247**

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is to improve the standard of care for patients with Benign Prostatic Hyperplasia (BPH), a broadly underserved market. Our first product is the UroLift® System, a minimally invasive device designed to treat lower urinary tract symptoms (LUTS) due to BPH.

**neotract**<sup>®</sup>

NeoTract, Inc.,  
4473 Willow Road, Suite 100  
Pleasanton, CA 94588  
Tel: (925) 401-0700 • (877) 408-9628  
Fax: (925) 401-0699  
[www.neotract.com](http://www.neotract.com)

© 2014 NeoTract, Inc. All rights reserved. Printed in the USA.

MAC00034-01 Rev B 02/2014